[Atezolizumab (urothelial carcinoma, first-line treatment) - benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018000050
German
Details
Project Status: Completed
Year Published: 2017
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Germany
MeSH Terms
  • Antibodies, Monoclonal
  • Carcinoma, Transitional Cell
  • Humans
  • Urologic Neoplasms
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.